



STATE OF WEST VIRGINIA
DEPARTMENT OF HUMAN SERVICES
BUREAU FOR MEDICAL SERVICES

Alex J. Mayer
Cabinet Secretary

Cynthia Beane, MSW, LCSW
Commissioner

**West Virginia Medicaid Drug Utilization Review Board Minutes
Feb 26, 2025**

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

Members:

Christopher Terpening, PharmD, PhD, Chair
C.K. Babcock, PharmD
Michael Ballow, PharmD
Chris Booth, PharmD
Scott Brown, RPh
Kate Forman, PharmD
Phillip Galapon, MD
Lester Labus, MD
Mary Nemeth-Pyles, MSN, RN, CS
Ernest Miller, DO

Members Absent:

David Gloss, MD, Vice Chair
Michael Lonsinger, PharmD

Department of Human Services (DoHS)/Bureau for Medical Services (BMS) Staff:

Vicki Cunningham, PharmD, Director of Pharmacy
Kristen Boustany, PharmD
Gail Goodnight, PharmD
Lori Moles, PharmD
Doug Sorvig, Data Analyst

Other Contract/State Staff Present:

Priya Shah, PharmD, Drug Utilization Review Coordinator
Joe Bergondo, PharmD – Change Healthcare
Roberta Capp, MD – Optum Rx
Zach Ganes – Gainwell
Angie Wowczuk, PharmD – Rational Drug Therapy Program (RDTP)
Cory Chambliss – Acentra Health
Scott Donald, PharmD – Acentra Health
Alena Mitchell, PharmD – Acentra Health

1. **INTRODUCTIONS**

- a. Dr. Chris Terpening, Chair, welcomed everyone to the Board meeting at 4:01 PM (EST). The DUR Board and others introduced themselves.

2. **APPROVAL OF MINUTES FROM Nov 13, 2024, DUR BOARD MEETING**

- a. A motion was made, seconded, and approved to accept the minutes from the previous DUR meeting with no further discussion.



3. **OLD BUSINESS**
 - a. None
4. **NEW BUSINESS**
 - a. **Speakers**
 - i. Written comments provided to the board prior to the meeting.
 - b. **Updates from January 22, 2025, Pharmaceutical & Therapeutics (P&T) Committee Meeting**
 - i. Dr. Joe Bergondo presented the Preferred Drug List (PDL) status updates from the January 22, 2025 P&T meeting.
 - c. **Prior Authorization Criteria. Attachment A**
 - i. Dr. Priya Shah presented the proposed prior authorization criteria.
 1. **Yorvipath**: approved as presented.
 2. **Dupixent**: approved as presented.
 3. **Alyftrek**: approved as presented.
 4. **Fluticasone HFA, Asmanex HFA**: approved as presented.
 5. **Zurzuva**: approved as amended.
 - a. Changed Step #5 to include other validated depression tools.
 6. **Casgev**: approved as presented.
 7. **Lyfgenia**: approved as presented.
5. **REPORTS – 4th Quarter of 2024**
 - a. **Gainwell Technologies Quarterly Report**: Zach Garnes presented an overview of the 2024 Fourth Quarter Report which included a review of the DUR Quarterly Overall Summary Report. Attachment B.
 - b. **Rational Drug Therapy Program**: Dr. Angela Wowczuk presented a summary of the prior authorization program for the Fourth Quarter of 2024. Attachment C.
 - c. **Acentra Health**: Dr. Alena Mitchell presented a summary of the Retro DUR (RDUR) interventions for the Fourth Quarter of 2024. Attachment D.
6. **OTHER BUSINESS**
 - a. None
7. **NEXT MEETING AND ADJOURNMENT**
 - a. The meeting concluded at 5:13 PM (EST).
 - b. Next meeting on May 21, 2025.

